Skip to main content
Delfa

← All assets

Melatonin

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

2

Recruiting

1

Completed

2

Sites

33

Countries

2

Endpoints

27

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 27 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Phase 3
1
Phase 4
1
Not applicable
2

Trials by status

Not yet recruiting
1
Recruiting
1
Completed
2
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
11
Behavior / neuropsychiatric
4
Other (unclassified)
3
Tau biomarkers
2
Neurodegeneration biomarkers
2
Fluid / digital biomarkers
2
Disease progression
1
Amyloid biomarkers
1
Other clinical outcomes
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 4 of 27 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Phosphorylated tau 217 (p-tau217)Tau

1

Neurofilament light (NfL)Neurodeg.

1

Mini-Mental State Examination (MMSE)Cognition

1

Phosphorylated tau 217 (p-tau217)Behavior

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00000171Study of Melatonin: Sleep Problems in Alzheimer's Disease

Melatonin

Alzheimer’s disease

Alzheimer's diseasePh 3Completed31-2
MCIThe Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Melatonin

MCI / preclinical Alzheimer’s

MMSE 24-30Ph 2Unknown1Oct 2010-
NCT03954899Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

Melatonin

Alzheimer’s disease, MCI / preclinical Alzheimer’s

CDR-SB ≤1Not applicableRecruiting1Nov 2025-
NCT06756828Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum

Melatonin

Alzheimer’s disease

Age 60-90Not applicableNot yet recruiting0Aug 2026-
NCT03066518Effect of Melatonin on Sleep Quality in Patients Dementia

Melatonin

Mixed / unspecified dementia

Age 60-95Ph 4Completed0Jan 201711

Showing 1-5 of 5 trials